Endobronchial Valve System Market Growth, Key Companies & Industry Trends

0
270

Endobronchial Valve System Market Overview

Endobronchial Valve System Market is growing at a CAGR of 7% during the forecast period 2024-2031.

Endobronchial valve systems are one-way bronchoscopic valves implanted to occlude airways feeding diseased lung segments most commonly used for bronchoscopic lung volume reduction in severe emphysema and for managing persistent air leaks (bronchopleural/bronchoalveolar fistulas). The public executive summary for the DataM Intelligence report notes the market is growing as clinical adoption increases and regulatory clearances for key valve systems expand.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/endobronchial-valve-system-market

Executive summary

Two commercial valve systems (Pulmonx’s Zephyr and Olympus’s Spiration) have driven much of the clinical and commercial adoption, with Zephyr holding breakthrough/expedited status in the U.S. and Spiration widely used for targeted lobar treatment. The devices differ in shape and mechanism (duckbill vs umbrella), but both offer a minimally invasive alternative to surgical lung-volume reduction in selected emphysema patients and provide an option for persistent air-leak management.

Why the market matters

  • Clinical alternative to surgery: Endobronchial valves let physicians achieve lung-volume reduction with bronchoscopy instead of open surgery for select patients, lowering peri-operative morbidity in appropriately selected cases.
  • Unmet needs in severe emphysema & persistent air leaks: The rising prevalence of COPD/emphysema and variable outcomes with conservative care create a durable addressable population for valve therapies.
  • Device innovation & regulatory momentum: FDA breakthrough designations and approvals have sped clinical uptake and stimulated product development and trials.

Market drivers

Rising adoption for severe emphysema as clinicians seek less-invasive lung-volume reduction options.
Clinical evidence of improved patient outcomes (better lung function, symptomatic relief, improved quality of life in responders) that supports broader use at tertiary centers.
Growing network of specialized interventional pulmonology and stroke/critical-care programs able to perform advanced bronchoscopic procedures.

Restraints & challenges

Procedure-related complications and device migration — these safety issues and case selection complexity limit adoption in some centers.
High device & procedure costs — affordability and reimbursement remain barriers in price-sensitive markets.
Need for robust evidence and appropriate patient selection tools (e.g., collateral ventilation assessment) to predict responders and justify therapy.

Product & segment snapshot

  • Device shape: Umbrella-shaped valves (e.g., Spiration) and duckbill-shaped valves (e.g., Zephyr) are the primary device forms identified in market segmentation.
  • Applications: Emphysema (lung-volume reduction), COPD care, treatment of persistent air leaks and other niche bronchoscopic indications.
  • End-users: Hospitals, specialty pulmonary clinics, academic research centres and ambulatory surgical centres performing bronchoscopic interventions.

Regional outlook

  • North America — largest market: Strong presence of major device makers, high procedure volumes, and concentrated interventional pulmonary expertise make North America the leading region.
  • Asia-Pacific — fastest growing: Expansion of specialized centers and rising awareness of advanced COPD therapies are driving adoption across APAC.
  • Europe, Latin America, MEA: Variable uptake depending on reimbursement, specialist training availability, and regulatory timelines.

Competitive landscape & key players

Major players named on the report page include Pulmonx Corporation (Zephyr) and Olympus / Spiration Valve System — with other device developers and smaller medtech firms active in this endovascular/bronchoscopic niche. Competitive differentiation centres on clinical evidence, valve design (migration resistance, ease of placement/removal), and distribution/clinical training networks.

Recent developments & market context

  • Regulatory milestones: Pulmonx’s Zephyr received breakthrough device recognition and expedited pathways in the U.S., accelerating clinical availability. Olympus’s Spiration also secured approvals for targeted emphysema indications.
  • COVID-19 considerations: Severe COVID-19 pneumonias and related air-leak complications briefly highlighted bronchoscopic valve insertion as a therapeutic option in select cases, impacting clinical demand and case mixes during the pandemic.

 

Buscar
Categorías
Read More
Other
Understanding the Global Cold Chain Monitoring Market Definition
The global Cold Chain Monitoring market is a dynamic and promising industry that has shown...
By Sunita Lawankar 2025-07-23 05:19:32 0 690
Other
Electronic Toll Collerction (ECT) Market to See Huge Growth by 2032
Introspective Market Research recently introduced the Electronic Toll Collerction (ECT)...
By Vishwanath Kalkundrikar 2025-09-12 14:14:30 0 430
Networking
Bath Bomb Market Demand will reach USD 35.9 Million by 2032 from USD 24.8 Million
Market Overview: According to the most recent research study by Kings Research, the...
By Abhishek Singh 2025-07-21 11:55:18 0 722
Networking
Tradition and Innovation Fueling the Virgin Coconut Oil Market
Tradition and Innovation Fueling the Virgin Coconut Oil Market Virgin coconut oil has...
By Prashant Hande 2025-09-09 12:01:59 0 330
Other
Indian escort klcc +601169901990
Indian escort klcc Offer an opulent and sensual experience that is ideal for those seeking such...
By Malaysia Kll 2025-09-17 11:24:47 0 365
SMG https://sharemeglobal.com